From: A one health framework to estimate the cost of antimicrobial resistance
Data element | Category of costs | Cost items |
---|---|---|
Direct costs | Costs of any treatment or prophylaxis of the patient borne by the health service (regardless of whether or not such costs are passed on to the payor/insurance company).a | − Cost of antibiotics for treating infections − Higher antibiotic expenses for empirical therapy due to a change in guidelines in response to higher frequency of drug-resistant infections − Cost of drug administration (central lines, etc.) − Cost of nursing care − Cost of cohorting (including cost of leaving not unoccupied beds due to isolation of one patient restricting the use of the bed(s) in the same room) − Extended length of stay, whereby ICU and non-ICU days should be separated − Costs due to de-colonisation, if applicable, (e. g. mupirocin), re-testing, e.g. additional follow-up screening − Cost of non-standard surgical prophylaxis in colonised/infected patients, with more expensive drugs − Costs of infection prevention and control interventions as screening at hospital admission or before surgery |
Costs of long- term consequences of AMR infection | − Cost of additional laboratory tests or imaging to diagnose site of infection or foci of distant infectious metastatic foci − Cost of diagnosing and treating adverse events to 2nd, 3rd line etc. (Drugs used against MDROs infection need careful monitoring of toxicity and efficacy, thus more laboratory and radiological tests.) − Extra hospital admissions, or extra care for rehabilitation (e.g., respiratory, mobility, cognitive, neurological) and/or treatments required for disease sequelae directly linked to the drug-resistant infection, like recurrent infection, kidney failure, amputation, neurological sequelae, extra surgery | |
Out-of-pocket expenditure borne by the patient for care | − Transport to and from the hospital (if the sole reason for the hospital admission was the infection) − Cost of funeral in cases of (attributable) death − Cost of (family/friend) care for the patient (e.g. hotel and meals to be near the hospital) due to excess length of stay of the patient related to the drug-resistant infection | |
Surveillance and control activitiesb | − Costs of enhanced surveillance − Cost of any screening that is triggered − Costs of isolation, cohorting or contact precautions to the health care system, including facility design and operational costs | |
Training of health care professionals and information/communication | − Costs of pre-service, in-service and continuous professional education per relevant cadre of human healthcare professional − Cost of any related public health or information campaign | |
Legal and insurance costs (patient) | − Additional insurance costs to cover problems associated specifically with resistance − Litigation costs, when suing hospitals for transmission of resistance infection | |
Legal and insurance costs (hospital) | − Litigation costs, when sued by patients for transmission of resistance infection − Costs of implementing or regulating and enforcing national robust, representative comprehensive surveillance programmes at all levels of health care from primary to tertiary levels | |
Indirect costs | Indirect patients’ costs: Loss of productivity/earning/opportunity when seeking treatment for the resistant infection (or colonisation) or dying from the resistant infection | − Value of foregone workdays value of foregone workdays because of disease sequelae related to the drug-resistant infection foregone treatments that depend on effectiveness of prophylaxis, like surgical interventions such as hip or knee replacements or caesarian sections − Foregone leisure time (NB: difficult to quantify) − Loss of productivity/earnings by family &visitors attending patient − Loss of caretaker (family/friend) productivity – (workdays foregone) − Psychological impact (factored in as QALY) − Other costs related to different life style (e.g. amputation leading to prosthesis or wheel chair; home renovation works to adapt to disability; nursing care costs, if unable to perform activities) |
Indirect hospital costs | − Reduced patient turnover and decreased revenues (due to longer hospital duration or to isolation/cohorting, or to decision not to perform a non-essential procedure –e.g. cosmetic surgery - etc.) − Reduced capacity of hospital (due to longer hospital duration or to isolation/cohorting − reputational costs borne by the hospital: any loss in hospital income related to the level of resistant infection/colonisation Note that a reduction in visits to one hospital may simply lead to an increase in visits for another. As this study takes a societal perspective only overall net reduction should be considered. (Assumption that no visits to the hospital are superfluous so that a reduction in visits due to fear of contracting a resistant pathogen imposes negative utility.) | |
Societal/government | − Financial burden on the government for disability benefits | |
Research and development of new antibiotics | − Cost to develop and bring a replacement drug to marketc |